NO20072636L - Formuleringer av substituerte benzoksazoler - Google Patents

Formuleringer av substituerte benzoksazoler

Info

Publication number
NO20072636L
NO20072636L NO20072636A NO20072636A NO20072636L NO 20072636 L NO20072636 L NO 20072636L NO 20072636 A NO20072636 A NO 20072636A NO 20072636 A NO20072636 A NO 20072636A NO 20072636 L NO20072636 L NO 20072636L
Authority
NO
Norway
Prior art keywords
formulations
substituted benzoxazoles
erβ
preparing
benzoxazoles
Prior art date
Application number
NO20072636A
Other languages
English (en)
Norwegian (no)
Inventor
James Andrew Provost
Mannching S Ku
Trevor I Armstrong
Zerina B Shafi
Marc S Tesconi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20072636L publication Critical patent/NO20072636L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20072636A 2004-12-02 2007-05-24 Formuleringer av substituerte benzoksazoler NO20072636L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63237504P 2004-12-02 2004-12-02
PCT/US2005/043407 WO2006060532A2 (en) 2004-12-02 2005-11-30 Formulations of substituted benzoxazoles

Publications (1)

Publication Number Publication Date
NO20072636L true NO20072636L (no) 2007-08-13

Family

ID=36565706

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072636A NO20072636L (no) 2004-12-02 2007-05-24 Formuleringer av substituerte benzoksazoler

Country Status (22)

Country Link
US (1) US20060121110A1 (es)
EP (1) EP1850833A2 (es)
JP (1) JP2008521919A (es)
KR (1) KR20070089921A (es)
CN (1) CN101128188A (es)
AR (1) AR053653A1 (es)
AU (1) AU2005311823A1 (es)
BR (1) BRPI0518786A2 (es)
CA (1) CA2589033A1 (es)
CR (1) CR9144A (es)
GT (1) GT200500349A (es)
IL (1) IL183393A0 (es)
MX (1) MX2007006564A (es)
NI (1) NI200700139A (es)
NO (1) NO20072636L (es)
NZ (1) NZ555395A (es)
PE (1) PE20061083A1 (es)
RU (1) RU2007120253A (es)
SV (1) SV2006002317A (es)
TW (1) TW200626144A (es)
WO (1) WO2006060532A2 (es)
ZA (1) ZA200705011B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600339A1 (en) * 2005-03-08 2006-09-14 Wyeth Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and their use as estrogen receptor modulators
AU2007215131A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of ERbeta selective ligands
PE20071019A1 (es) * 2006-03-06 2007-10-29 Wyeth Corp Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos
PE20071315A1 (es) * 2006-03-06 2008-02-14 Wyeth Corp Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos
TW200800179A (en) * 2006-03-06 2008-01-01 Wyeth Corp Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
AR059743A1 (es) * 2006-03-06 2008-04-23 Wyeth Corp Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20050165000A1 (en) * 2002-04-10 2005-07-28 Robertson Sandra K. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant

Also Published As

Publication number Publication date
KR20070089921A (ko) 2007-09-04
RU2007120253A (ru) 2009-01-10
AU2005311823A1 (en) 2006-06-08
NZ555395A (en) 2009-07-31
BRPI0518786A2 (pt) 2008-12-09
CR9144A (es) 2007-11-23
WO2006060532A2 (en) 2006-06-08
CN101128188A (zh) 2008-02-20
PE20061083A1 (es) 2006-11-14
EP1850833A2 (en) 2007-11-07
CA2589033A1 (en) 2006-06-08
MX2007006564A (es) 2007-06-19
SV2006002317A (es) 2006-06-26
JP2008521919A (ja) 2008-06-26
WO2006060532A3 (en) 2006-11-16
US20060121110A1 (en) 2006-06-08
AR053653A1 (es) 2007-05-16
ZA200705011B (en) 2010-01-27
NI200700139A (es) 2008-05-09
GT200500349A (es) 2006-07-03
TW200626144A (en) 2006-08-01
IL183393A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20070391L (no) Jernsulfatbasert fosfatadsorbent
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA201000491A1 (ru) Аминометилзамещенные тетрациклиновые соединения
NO20093060L (no) Spirosykliske sykloheksanderivater
NO20090052L (no) Nye forbindelser
NO20083153L (no) Kjemiske forbindelser
NO20044261L (no) Indazoler substituerte med en anticanceros aktivitet
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
NO2012017I1 (no) Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen.
NO20081160L (no) Benzimidazoltiofen forbindelser
SE0301700D0 (sv) Novel compounds
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
EA201070518A1 (ru) Композиция по уходу за волосами
NI200700139A (es) Formulaciones de benzoxazoles sustituidos
SE0401762D0 (sv) Novel compounds
NO20073551L (no) Nikotinacetylkolinreseptorligander
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
NO20063354L (no) Nikotinacetylcholinreseptorligander
MX2007006565A (es) Formulaciones de benzoxazoles sustituidos.
NO20073772L (no) Preparater som omfatter et epotilon, og fremstillingsfremgangsmate
RU2007122391A (ru) S-миртазапин для лечения приливов
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application